Whole transcriptome analysis of osteoclasts after treatment with or without etelcalcetide

Phosphate binders, vitamin D analogs, and calcimimetics have recently been used to control the disturbed mineral metabolism in chronic kidney disease-mineral and bone disorder (CKD-MBD). Etelcalcetide , a new calcimimetic agent approved by is considered by patients due to its convenience as an intravenous form which easily affordable during dialysis sessions. In this study, we evaluated the effects of etelcalcetide on osteoclasts. Overall design: RAW264.7 cells were incubated with RANKL (50 ng/mL) with or without etelcalcetide (4 µM) for 5 days.